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Abstract
Objective: Febrile seizures are the most common form of childhood seizures. Fever is induced by pro-
inflammatory cytokines during infection, and pro-inflammatory cytokines may trigger the development of febrile
seizures. In order to determine whether active inflammation, including high mobility group box-1 (HMGB1) and
pro-inflammatory cytokines, occurs in children with febrile seizures or epilepsy, we analyzed cytokine profiles of
patients with febrile seizures or epilepsy.
Methods: Forty-one febrile seizure patients who visited the emergency department of Seoul National University
Boramae Hospital from June 2008 to May 2009 were included in this study. Blood was obtained from the febrile
seizure child patients within 30 minutes of the time of the seizure; subsequently, serum cytokine assays were
performed. Control samples were collected from children with febrile illness without convulsion (N = 41) and
similarly analyzed. Serum samples from afebrile status epilepticus attacks in intractable epilepsy children (N = 12),
afebrile seizure attacks in generalized epilepsy with febrile seizure plus (GEFSP) children (N = 6), and afebrile non-
epileptic controls (N = 7) were also analyzed.
Results: Serum HMGB1 and IL-1b levels were significantly higher in febrile seizure patients than in fever only
controls (p < 0.05). Serum IL-6 levels were significantly higher in typical febrile seizures than in fever only controls
(p < 0.05). Serum IL-1b levels were significantly higher in status epilepticus attacks in intractable epilepsy patients
than in fever only controls (p < 0.05). Serum levels of IL-1b were significantly correlated with levels of HMGB1, IL-6,
and TNF-a (p < 0.05).
Conclusions: HMGB1 and pro-inflammatory cytokines were significantly higher in febrile seizure children. Although
it is not possible to infer causality from descriptive human studies, our data suggest that HMGB1 and the cytokine
network may contribute to the generation of febrile seizures in children. There may be a potential role for anti-
inflammatory therapy targeting cytokines and HMGB1 in preventing or limiting febrile seizures or subsequent
epileptogenesis in the vulnerable, developing nervous system of children.
Background
Febrile seizures are the most common form of child-
hood seizures, occurring in 2%-5% of children younger
than 6 years old [1]. Febrile seizures are defined as sei-
zures that occur during a febrile state and without an
obvious central nervous system infection. Fever is
induced by pro-inflammatory cytokines such as inter-
leukin (IL)-1b, IL-6, and tumor necrosis factor (TNF)-
a during infections. The fever threshold temperature
for febrile seizures varies among individuals, as well as
by age and maturation [2]. Genetic susceptibility to
inflammation may influence the fever threshold tem-
perature for febrile seizures, and 17-30% of febrile sei-
zure patients have a family history of febrile seizures
[2]. IL-1b biallelic polymorphism in the promoter
region at the -511 position is significantly higher in
febrile seizure patients than in fever only children, and
this polymorphism results in an increase in IL-1b pro-
duction [3,4]. However, others have failed to demon-
strate a significant association between IL-1b (-511)
and febrile seizures [5,6]. The association of IL-1b
gene polymorphism and susceptibility to febrile
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seizures is still controversial. Increased levels of IL-6,
and IL-1-receptor antagonist/IL-1b ratio have been
reported in the plasma of febrile seizure patients [3].
Viruses as causative agents of febrile seizures have
been demonstrated in several reports. Neurotropic
viruses, such as herpes and influenza A, are commonly
associated with febrile seizures [7,8].
Pro-inflammatory cytokines may trigger febrile sei-
zures. In experimental animals, intraventricular injection
of IL-1b reduces the seizure threshold in 14-day old
mice subjected to hyperthermia, while IL-1b knock-out
mice had an increased seizure threshold [9]. IL-1b
increases glutamatergic neurotransmission and lowers
the peak magnitude of GABA-mediated currents [10],
supporting the role of pro-inflammatory cytokine contri-
bution to the generation of fever-induced seizures [9].
Also, IL-1b prolongs the duration of electroencephalo-
graphic seizure [11].
High mobility group box-1 (HMGB1) has been shown
to be a key mediator of inflammatory diseases. HMGB1
is a nuclear protein that triggers inflammation, binds to
lipopolysaccharides (LPS) and IL-1, and initiates and
synergizes with a Toll-like receptor (TLR) 4-mediated
pro-inflammatory response [12]. After pro-inflammatory
stimulation, such as that by LPS, TNF-a, IL-1, IL-6 and
IL-8, HMGB1 is actively released from activated mono-
cytes and macrophages. Regulation of HMGB1 secretion
is important for control of HMGB1-mediated inflamma-
tion and is dependent on various processes such as
phosphorylation by calcium-dependent protein kinase C
[13], as well as acetylation and methylation [14]. In a
recent study, HMGB1 and TLR4 were involved in the
generation and recurrence of seizures in experimental
animals [15,16].
Cytokine analyses in our previous study showed that
pro-inflammatory cytokine levels, including IL-1b, IL-8,
IL-12p70, and macrophage inflammatory protein (MIP)-
1b, were significantly high in the epileptogenic cortex of
intractable epilepsy children [17]. In addition, levels of
IL-6 and MCP-1 were significantly high in patients with
a family history of epilepsy. Active neuroinflammation,
such as a marked activation of microglia and astrocytes
as well as marked cellular injury, were also observed in
epileptogenic brain tissue, supporting the suggestion
that neuroinflammation may contribute to epileptogen-
esis in the developing brain.
In order to determine whether active inflammation,
including HMGB1 and pro-inflammatory cytokines,
occurs in children with febrile seizures and pediatric
epilepsy, we analyzed cytokine profiles in the serum of
child patients with febrile seizures or epilepsy and
assessed the correlation between cytokine levels and feb-
rile seizures.
Materials and methods
Patient information
Forty-one febrile seizure patients who visited to emer-
gency department of Seoul National University Boramae
Hospital from June 2008 to May 2009 were included in
this study (Table 1). Blood was obtained from patients
within 30 minutes of the time of seizure, and serum was
immediately separated and frozen for subsequent cyto-
kine assay. Patient inclusion criteria were age between 6
months and 6 years, body temperature ≥38.5°C, C-reac-
tive protein (CRP) ≤2.0, and presented no other identifi-
able cause of the seizure. Clinical data for familial
febrile seizure history, earlier febrile seizure attacks, as
well as duration and semiology of febrile seizures were
obtained from the patients’ parents. Family history was
regarded as positive when febrile seizures occurred in
first-degree relatives. Laboratory findings, including
complete blood counts (CBC), blood chemistry, and
CRP, were checked at the time of seizure. CRP levels
higher than 2.0 were excluded due to presumptive pre-
sence of bacterial infection. Febrile seizure patients were
classified into two types: typical type for whom febrile
seizures persist for < 15 minutes, are generalized tonic-
clonic, and only occur once within 24 hours; and atypi-
cal types for whom seizures persist for > 15 minutes, or
are partial seizures, or recur within 24 hours of the
initial attack. Control samples were collected from chil-
dren with febrile illness, but without convulsion (N =
41). Control groups were matched for age and tempera-
ture criteria and had no convulsions during the febrile
illness and no known history of previous febrile seizures.
Control blood serum was collected and frozen as above.
In addition, blood serum was collected and frozen from
afebrile status epilepticus attacks in intractable epilepsy
children (N = 12), afebrile seizure attacks in GEFSP chil-
dren (N = 6), and afebrile non-epileptic controls (N = 7)
for cytokine assay in order to subtract fever effects from
the cytokine levels. The study was approved by the
Institutional Review Board at the Seoul National Univer-
sity Boramae Medical Center (20080918/06-2008-74/76).
Informed consent was obtained from each child’s
parents.
Cytokine measurement
Levels of pro-inflammatory cytokines including HMGB1,
IL-1b, IL-6, interferon (IFN)-b, TNF-a, and anti-inflam-
matory cytokine IL-10 were measured using commer-
cially available, enzyme-linked immunosorbent assay
(ELISA) kits according to the manufacturer’s instruc-
tions (for HMGB1, Shino-Test Corp., Tokyo, Japan [17];
for IL-1b, IFN-b, TNF-a, and IL-10, Panomics Inc., Red-
wood City, CA, USA; for IL-6, R&D Systems, Minneapo-
lis, MN, USA). Samples were analyzed in duplicate and
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compared with controls. The detection limits were 0.2
ng/mL for HMGB1, 0.27 pg/mL for IL-1b, 0.23 pg/mL
for IL-6, 0.21 pg/mL for IFN-g, 0.49 pg/mL for TNF-a
and 0.22 pg/mL for IL-10.
Statistical Analysis
The c2 test was used to compare the clinical character-
istics between febrile seizure patients and the controls.
The Mann-Whitney test was used to compare serum
cytokine levels and laboratory findings between con-
trols and febrile seizure patients. The Spearman’s rank
correlation coefficient was calculated to detect signifi-
cant correlations between cytokine levels. The Kruskal
Wallis test was used to compare cytokine levels among
afebrile controls, febrile controls, and four seizure
groups (first attack febrile seizure, recurrent attack feb-
rile seizure, afebrile seizure attack in GEFSP, and afeb-
rile status epilepticus attacks in intractable epilepsy
patients). GraphPad Prism v. 4.0 (GraphPad Software
Inc., San Diego, CA, USA) was used to perform the
above tests. Values are expressed as means, and statis-
tical significance of differences was set as p < 0.05 for
all tests.
Results
Patient characteristics
Table 1 summarizes the patient’s clinical data. Forty-
one febrile seizure patients and 41 control children
with febrile illness without convulsion were included
in this study. The mean age of febrile seizure patients
was 2.1 years. Boys were more prevalent than girls
were (respectively, 71% vs. 29%). Eleven (27%) patients
had a family history of febrile seizures and fourteen
(34%) patients exhibited atypical types of febrile sei-
zures (Table 2). Twenty-eight patients (68%) had their
first febrile seizure attack and thirteen patients (32%)
had experienced previous febrile seizure attacks. Feb-
rile seizure patients and febrile children without sei-
zures did not significantly differ by sex, age, and
laboratory data.
Serum cytokine levels in the febrile seizure patients;
increased IL-1b, IL-6, IL-10 and HMGB levels
In febrile seizure patients, serum IL-1b levels were at a
4-fold increase and HMGB1 levels were at a 1.3-fold
increase higher than the fever only controls (Table 3,
both p < 0.05). Serum levels of IL-6 were at a 1.8-fold
increase and IL-10 were at a 2.8-fold increase in febrile
seizure patients higher than the fever only controls,
although statistically not significant (Table 3, p = 07 and
p = 0.05). There were no differences in serum IFN-g
and TNF-a levels between febrile seizure patients and
fever only controls (Table 3).
In comparisons of the subgroups of febrile seizure
patients with the fever only control, typical febrile sei-
zure patients showed a 4.2-fold increase of IL-1b and a
1.9-fold increase of IL-6 levels higher than the fever
only controls (Table 3, both p < 0.05). Both atypical
febrile seizure and first attack febrile seizure patients
showed a 1.5- and a 1.4-fold increase of HMGB1 levels
higher than the fever only controls (Table 3, both p <
0.05). The IL-1b levels were at an 8.1-fold increase in
patients with recurrent febrile seizure attacks than
those with first febrile seizure attack, although statisti-
cally not significant (Table 3, p = 0.27). IL-10 levels
showed a 6.6-fold increase in children with recurrent
febrile seizure attacks higher than the fever only con-
trols (Table 3, p = 0.06). Febrile seizure patients with-
out a family history of febrile seizures showed a 3.5-
fold increase of IL-10 levels (Table 3, p < 0.05) above
the fever only controls and a 3.7-fold increase above
those with FS without a family history of febrile sei-
zures (Table 3, p = 0.31).
Table 1 Clinical findings of febrile seizure, epilepsy, and control children
Fever only control
(N = 41)
Febrile seizure
(N = 41)
Afebrile control
(N = 7)
Afebrile seizure
(N = 6)
Afebrile
SE
(N = 12)
Age (year) 3.1 2.1 7.9 7.6 6.3
Male/Female 24/17 29/12 3/4 4/2 8/4
BT at admission(°C) 38.4 39.0 36.6 37.0 36.5
WBC count
(per mm3)
11,719 12,068 7,540 8,716 9,560
CRP 0.91 0.95 0.4 0.6 0.8
SE, status epilepticus; BT, body temperature
Table 2 Subgroups of febrile seizure patients
Febrile seizure patients (N = 41)
Family history of FS Positive 11 (27%)
Negative 30 (73%)
FS history First attack 28 (68%)
Recurrent 13 (32%)
FS type Typical 27 (66%)
Atypical 14 (34%)
FS, febrile seizure
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Serum cytokine levels in the afebrile control, febrile
control, and afebrile various seizure groups
1. IL-1b
The mean IL-1b level of the afebrile control children
was 2.0 pg/mL, while that for the febrile control was 3.1
pg/mL. The mean IL-1b level in afebrile status epilepti-
cus attacks in intractable epilepsy patients was at a 11.7-
fold increase higher than that of the afebrile controls
(23.4 vs. 2.0 pg/mL) and a 7.5-fold increase higher than
of fever only controls (Table 3, 23.4 vs. 3.1 pg/mL, p <
0.05). Comparisons of IL-1b levels among afebrile and
febrile controls and the four seizure groups (first and
recurrent febrile seizures, afebrile seizures in GEFSP and
afebrile status epilepticus in intractable epilepsy
patients) showed significantly higher levels in the afeb-
rile status epilepticus in intractable epilepsy and the
recurrent febrile seizure groups (Figure 1A, p < 0.05).
2. IL-6
The mean IL-6 level of afebrile controls was 34.7 pg/
mL, while that of febrile controls was 134.0 pg/mL, and
that of afebrile status epilepticus attacks in intractable
epilepsy patients was 51.4 pg/mL. Comparisons of IL-6
levels among afebrile and febrile controls, and the four
seizure groups showed significantly higher IL-6 levels in
first and recurrent attack febrile seizure patients (Figure
1B, p < 0.05).
3. TNF-a
The mean TNF-a level of afebrile controls was 3.4 pg/mL,
while that in febrile controls was 5.6 pg/mL, and that in
afebrile status epilepticus attacks in intractable epilepsy
patients was 14.2 pg/mL. Afebrile seizure patients showed
a 57% decrease of TNF-a levels of febrile controls (Table
3, p < 0.05). Comparisons of TNF-a levels among afebrile
and febrile controls, and the four seizure groups showed
higher levels in the afebrile status epilepticus attacks in
intractable epilepsy patients and the recurrent attack feb-
rile seizure groups (Figure 1C, p = 0.06).
4. HMGB1
The mean HMGB1 level in the serum of afebrile con-
trols was 9.0 ng/mL, that in febrile control was 24.8 ng/
mL, and that in afebrile status epilepticus attacks in
intractable epilepsy patients was 30.1 ng/mL. In compar-
isons of HMGB1 levels between afebrile controls, febrile
controls and the four seizure groups, there were trends
of higher HMGB1 levels in both febrile seizures and
afebrile status epilepticus attacks in intractable epilepsy
patients than in the febrile and afebrile controls, but this
was not statistically significant (Figure 1D, p = 0.11).
5. IFN-g
The mean IFN-g level of afebrile controls was 20.8 pg/
mL, that in febrile controls was 84.2 pg/mL, and that in
afebrile status epilepticus attacks in intractable epilepsy
patients was 21.4 pg/mL. Comparisons of IFN-g levels
among afebrile and febrile controls, and the four seizure
groups showed no significant differences (Table 3).
6. IL-10
The mean IL-10 level of afebrile controls was 2.7 pg/
mL, that in febrile controls was 8.3 pg/mL, and that in
afebrile status epilepticus attacks in intractable epilepsy
patients was 0.6 pg/mL. Afebrile seizure patients and
afebrile status epilepticus patients with intractable epi-
lepsy showed significantly decreased IL-10 levels than
that of febrile and afebrile controls (2.6 pg/mL & 0.6
pg/mL, p < 0.05). There were no significant differences
of IL-10 levels among afebrile controls, febrile controls
and the four seizure groups (Table 3).
The correlations between the various cytokines
IL-1b serum levels were significantly correlated with
HMGB1, IL-6, and TNF-a levels (respectively: Figures
2A, B, and 2C; r = 0.28, r = 0.25, and r = 0.45; all p <
0.05), but not with IL-10 and IFN-g. Serum IL-6 levels
were significantly correlated with IL-1b and TNF-a
levels (respectively: Figures 2B and 2D; r = 0.25 and r =
Table 3 Comparisons of cytokine levels between fever only control and febrile seizure subgroups
Groups (No.) IL-1b IL-6 HMGB1 IFN-g TNF-a IL-10
(pg/mL) (pg/mL) (ng/mL) (pg/mL) (pg/mL) (pg/mL)
Fever only control (41) 3.1 ± 0.8† 134.0 ± 22.7 24.8 ± 2.5 84.2 ± 38.6 5.6 ± 2.9 8.3 ± 2.6
Febrile seizures (41) 12.0 ± 5.3* 247.1 ± 43.0 32.6 ± 3.0* 73.5 ± 20.9 5.0 ± 1.8 23.6 ± 13.4
Typical FS (27) 12.9 ± 7.6* 260.1 ± 50.4* 30.5 ± 3.8 66.5 ± 21.6 3.0 ± 0.9 28.5 ± 20.3
Atypical FS (14) 10.4 ± 4.9 228.3 ± 81.2 36.6 ± 5.0* 86.9 ± 45.9 9.0 ± 5.0 14.2 ± 3.8
First FS (28) 3.7 ± 0.7 252.7 ± 53.5 35.0 ± 3.9* 74.6 ± 21.3* 1.9 ± 0.6 9.2 ± 2.2
Recurrent FS (13) 30.1 ± 15.7 241.7 ± 73.0 27.3 ± 4.7 70.9 ± 48.8 11.8 ± 5.3 54.6 ± 41.8
FS without FHx (30) 13.0 ± 6.9 241.6 ± 49.3 31.8 ± 3.6 62.8 ± 22.5 5.2 ± 2.4 29. 4 ± 18.2*
FS with FHx (11) 9.4 ± 5.6 270.1 ± 89.2 34.7 ± 5.9 102.6 ± 48.5 4.7 ± 2.1 7.8 ± 2.7
* indicates a significant (p < 0.05) difference compared to fever only control (Mann-Whitney test).
FS, febrile seizure; FHx, family history; SE, status epilepticus
†; mean ± standard error of mean
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0.28; both p < 0.05), but were not correlated with
HMGB1, IL-10, and IFN-g levels.
Discussion
This is the first study demonstrating a significant ele-
vation of HMGB1 in the serum of febrile seizure
patients. Moreover, serum levels of other pro-inflam-
matory cytokines, including IL-1b, IL-6, and the anti-
inflammatory cytokine IL-10 were significantly higher
among our patients with febrile seizures. IL-1b level
increase was related to seizure recurrence and dura-
tion, as seen with the higher levels of IL-1b in recur-
rent febrile seizure or afebrile status epilepticus
patients. In addition, IL-1b levels were significantly
and positively correlated with HMGB1 levels and with
other pro-inflammatory cytokines (IL-6 and TNF-a),
supporting the association of the cytokine network in
febrile seizures.
HMGB1 is a highly conserved, ubiquitously expressed
protein [18] and is actively secreted from monocytes
and macrophages in response to challenges with LPS
[19]. HMGB1 binds to and transfers LPS, consequently
increasing LPS-induced TNF-a production in human
peripheral blood mononuclear cells [13]. HMGB1 is pas-
sively released from necrotic cells, but not from apopto-
tic cells, thereby creating a signal for the organism to
distinguish between the two types of cell death [20].
Several clinical studies have reported that serum
HMGB1 levels are elevated in patients with infection
and/or systemic inflammatory response syndrome, than
in healthy control individuals [19,21]. HMGB1 is
involved in various diseases without obvious infections;
A B
DC
Figure 1 Serum cytokine levels in different seizure patients. (A-D) Mean serum cytokine levels of IL-1b (A), IL-6 (B), TNF-a (C), and HMGB1
(D) in afebrile control (N = 7), afebrile seizure (sz) attacks in generalized epilepsy with febrile seizure plus patients (GEFSP) (N = 6), afebrile status
epilepticus (SE) attacks in intractable epilepsy patients (N = 12), febrile controls without seizures (N = 41), First febrile seizure attack (FS) patients
(N = 28) and recurrent FS attack patients (N = 13). (A) IL-1b levels are significantly high in both groups of afebrile SE and recurrent FS. (B) IL-6
levels are significantly high in the groups of first FS and recurrent FS (all, p < 0.05). (C and D) The trends toward high serum levels of TNF-a and
HMGB1 in afebrile SE patients and recurrent FS patients, were statistically not significant (p = 0.06 and p = 0.11, respectively). Error bar, standard
error of mean.
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for example, rheumatoid arthritis [22], hemorrhagic
shock [23], cerebral and myocardial ischemia [24], acute
lung injury [25], and acute pancreatitis [26]. HMGB1 is
highly expressed in human epileptogenic brain, and
antagonists of HMGB1 and TLR4 have been demon-
strated to retard seizure precipitation and to decrease
acute and chronic seizure recurrence in epilepsy animals
[15]. These findings suggest a role for the HMGB1-
TLR4 axis in epilepsy. In our study, serum levels of
HMGB1 were significantly higher in febrile seizure
patients and showed a positive correlation with IL-1b
levels. Our results, together with those from other stu-
dies, suggest that HMGB1 activation is an important
feature associated with epilepsy and febrile seizures.
IL-1b serum levels were significantly higher in our
febrile seizures patients than in febrile children without
seizures. IL-1b has been shown to have potent pro-con-
vulsant properties in experimental animals [27]. IL-1b
acts on astrocytes to increase glutamate release via
TNF-a production [28], resulting in elevated extracellu-
lar glutamate levels and hyper-excitability. Also, IL-1b
can stimulate IL-6 release [29]. In our patients, IL-1b
levels were significantly correlated with IL-6, HMGB1,
and TNF-a levels. In our previous work using epilepto-
genic brain cortices of children with intractable epilepsy,
pro-inflammatory cytokines, IL-1b, IL-8, IL-12p70, and
MIP-1b were increased significantly above those in non-
epileptogenic control brain cortices [30]. Our patients
with intractable epilepsy experiencing status epilepticus
attacks also showed high IL-1b, IL-6 and HMGB1 levels.
These results together suggest that active inflammation
does occur in febrile seizures and pediatric epilepsy, and
it may play a common pathologic role in febrile seizures
and epilepsy.
Since cytokine levels were measured with blood taken
30 min after the seizure, the acute effect of seizures
could not be distinguished from a persistent inflamma-
tory tone in febrile seizure patients. Seizures themselves
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Figure 2 Correlation between serum cytokine levels in seizure patients. (A-D) Correlation between serum levels of IL-1b and HMGB1 (A), IL-
1b and IL-6 (B), IL-1b and TNF-a (C), and IL-6 and TNF-a (D) in febrile patients (N = 82). IL-1b levels are significantly correlated with HMGB1, IL-6,
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can activate the sympathetic nervous system and induce
the release of catecholamines [31,32], resulting in cyto-
kine release from peripheral blood mononuclear cells
[33]. However, in our study, patients with recurrent feb-
rile seizure attacks had much higher IL-1b and TNF-a
levels than patients with first attack febrile seizures,
although interictal cytokine levels were not available
after acute seizures. In animal models of prolonged feb-
rile seizures, IL-1b was significantly high in the hippo-
campus for over 24 hours and was elevated chronically
only in rats developing spontaneous limbic seizures after
febrile status epilepticus [9,34]. These findings suggest
that inflammatory responses in febrile seizures are
accentuated by their repetition and increase the likeli-
hood of febrile seizure recurrence.
Interestingly, no increase in serum IL-1b was detected
in our children with fever but no seizures (3.1 pg/mL),
as compared to controls without fever and with no sei-
zures (2.0 pg/mL). In another study, similarly low IL-1b
blood levels of 3.4 pg/mL were reported in the febrile
control group [35]. This lack of increase may be the
result of excluding patients with presumptive bacterial
infections, because LPS is the main inducer for the
synthesis of IL-1b [36]. Also, IL-1b is usually difficult to
detect because of its binding to large proteins such as
a-2 macroglobulin and complement [37]. Furthermore,
fever could occur independently of IL-1 or TNF activity
during infections, and the cytokine-like property of TLR
signal transduction could be one explanation [38].
The sources of the serum cytokine in febrile seizures
patients are not clear. The main source of IL-1 is mono-
cytes in the periphery and microglial cells in the nervous
system, which upon activation secrete the cytokines.
Cytokines are produced by astrocytes and some neurons
in the CNS by LPS and other stimuli [39,40]. Under
normal conditions, the levels of IL-1 are low, both in
the circulation and in the CNS, whereas upon infection
or injury, IL-1 levels increase abruptly but transiently,
returning to normal within 8 h in healthy, young mouse
brain [41]. Therefore, high serum levels of IL-1b may
reflect high levels in the CNS. However, conflicting
results about IL-1b levels have been reported in periph-
eral blood and CSF of children with febrile seizures,
such as high in plasma but not in CSF [42], or high in
CSF but not in serum [43] or increase in neither serum
nor CSF [35]. These results potentially reflect difficulties
in obtaining clinical samples and measuring free IL-1b.
The possible sources of the serum cytokine increases in
febrile seizures may be peripheral mononuclear cells,
CSF-blood exchange, and leakage from the brain reticu-
loendothelial system.
A dual role of IL-6 in seizures has been demonstrated
in several animal models. IL-6 knockout mice showed
an increased seizure susceptibility to glutamate receptor
agonists [44]. Transgenic mice over-expressing IL-6 in
astrocytes were also reported to have an increased sei-
zure susceptibility to glutamate receptor agonists, prob-
ably due to reduced GABA-mediated inhibition [45]. In
developing rats, intra-nasal administration of IL-6 pro-
longed the latency and shortened the duration of
hyperthermia-induced seizures, suggesting an anti-con-
vulsant effect to febrile seizures [46]. On the other
hand, intranasal administration of IL-6 in adult rats exa-
cerbated the severity of seizures induced by pentylenete-
trazole, supporting a pro-convulsant effect [47]. In our
patients including only presumptive viral infections,
serum IL-6 was higher in febrile seizure children than in
fever only controls. Moreover, IL-6 levels in febrile sei-
zure patients were much higher than in afebrile seizure
attack patients. Higher IL-6 and IFN-a levels have been
reported in patients with influenza-associated febrile sei-
zures compared to those without febrile seizures [3,48].
These findings, with our results, may support the pro-
convulsant action of IL-6 in febrile seizures.
IL-10 is a multifunctional anti-inflammatory cytokine
produced by monocytes, macrophages, lymphocytes, as
well as microglia and inhibits the production of pro-
inflammatory cytokines, including IL-1, IL-6, IL-8, and
TNF-a [49]. Peripheral blood mononuclear cells from
febrile seizure patients have shown increased IL-10 pro-
duction by LPS [50]. In IL-10 injected animals, the feb-
rile seizure threshold was significantly higher than that
in controls, suggesting that IL-10 is associated with a
resistance to febrile seizures [51]. Previously, plasma IL-
10 levels showed no difference between febrile seizures
and controls [3]. However, in our patients, IL-10 levels
were higher in recurrent febrile seizure patients than in
first attack febrile seizure patients and were also higher
in patients without a family history of febrile seizures
than in patients with family history. These findings may
reflect compensatory activation of anti-inflammatory or
anti-convulsive mechanisms, or mechanism defects in
the anti-inflammatory role of IL-10 in febrile seizure
families; further studies into the role of IL-10 are
warranted.
TNF-a causes both detrimental and beneficial effects
on brain function depending on its concentration, tar-
geted cells, duration of exposure and the specific recep-
tor subtypes [52,53]. TNF-a is rapidly upregulated in
the CNS by seizures, and intrahippocampal injection of
TNF-a potently inhibit seizure in a mice model of epi-
lepsy [54]. In our children with acute and brief seizures,
either febrile or afebrile, serum TNF-a was decreased,
or at least not increased, supporting that TNF-a is not
involved in the mechanisms by which seizures are trig-
gered. On the other hand, transgenic mice over-expres-
sing high amounts of TNF-a in astrocytes developed
spontaneous seizures, [55] and TNF-a has been shown
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to increase excitatory postsynaptic currents in hippo-
campal neurons [56] and to decrease GABAA-mediated
inhibitory synaptic strength, leading to increased seizure
susceptibility [57,58]. Our recurrent febrile seizure
patients showed higher serum TNF-a levels than first
attack febrile seizure patients, and afebrile status epilep-
ticus attacks in intractable epilepsy patients showed
higher serum TNF-a level than short-duration seizure
attacks in GEFSP patients, supporting that chronic or
recurrent expression of TNF-a may change susceptibil-
ity to seizures.
The causative role of cytokines in epileptogenesis
remains to be elucidated. Cytokines may contribute initi-
ally to incite seizures in the developing brain after being
induced by seizure or tissue injury, and they may exacer-
bate tissue injury and promote further seizures. Further-
more, cytokine gene polymorphisms have been linked to
epilepsy susceptibility [4]. Thus, it may be worthwhile to
explore further a possible link between febrile seizures
and genetic susceptibility to inflammation.
In summary, HMGB1 and pro-inflammatory cytokines
were significantly higher in febrile seizure patients.
Although it is not possible to infer causality from
descriptive human studies, our data suggest that
HMGB1 and the cytokine network may contribute to
the generation of febrile seizures in children. Pro-
inflammatory cytokine production may promote sei-
zures, further exacerbate epilepsy, and may cause subse-
quent intractable epilepsy. If so, there may be a
potential role for anti-inflammatory therapy targeting
cytokines and HMGB1 as a novel therapeutic strategy to
prevent or limit febrile seizures or subsequent epilepto-
genesis in the vulnerable, developing nervous system of
children.
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